Results of a small Johns Hopkins Children’s Center study show that hospitalized children given high-dose IV infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an increased risk for kidney damage — an often reversible but sometimes serious complication….
Microcapsule Eliminates Toxic Punch of Experimental Anti-Cancer Drug
Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pancreatic cancer tissue. The encapsulated…
Combo Treatment Benefits Women with Metastatic Breast Cancer
Results of a Phase 2, open-label, dose-confirmation study of eribulin in combination with capecitabine, suggests that this therapy is efficacious in women with metastatic breast cancer (overall response rate 42.9% and clinical benefit rate 57.1%), with a safety and tolerability profile…
New Cause of Child Brain Tumor Identified
Doctors and scientists from The University of Manchester have identified changes in a gene, which can increase the risk of developing brain tumors in children with a rare inherited condition called Gorlin syndrome. Gorlin syndrome causes an increased risk of developing…
HIV Drug Blocks Bone Metastases in Prostate Cancer
Although prostate cancer can be successfully treated in many men, when the disease develops bone metastases, it is eventually lethal. In a study published online in the journal Cancer Research, researchers show that the receptor CCR5, best known for its role…
Big Data to Make Big Difference in Childhood Cancer Treatment
University of Technology Sydney (UTS) research crunching vast amounts of data on childhood cancer to better tailor treatment is one step closer to assisting clinicians as the collaboration with the Kids Research Institute at The Children’s Hospital at Westmead celebrates 12…
New Ways to Drain Cancer’s identify by Researchers
Scientists at the University of Manchester have discovered a potential weakness in cancer’s ability to return or become resistant to treatment, by targeting the ‘fuel’ part of stem cells which allows tumors to grow. Cancer stem cells are particularly difficult to…
Last Patient Dosed in Phase 2a Alzheimer’s Study
Neurotrope, Inc. announced that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer’s disease (AD). The trial is being conducted under an Investigational New Drug (IND) application filed by…
A New Approach to Fighting Leukemia
Chronic myeloid leukemia develops when a gene mutates, causing blood-forming stem cells to grow rapidly into abnormal cells, known as leukemic tumors. The enzyme, Abl-kinase, is a member of the “kinase” family of enzymes, which serve as an “on” or “off”…